MRC1 and colorectal carcinoma: With respect to oncologic outcomes, MMR-deficient CRC is associated with a better prognosis and therapeutic responses because the MMR pathway is involved in triggering cell death after chemotherapy-induced DNA damage (Gryfe et al., 2000).